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Background: Pancreatic cancer shows a highly aggressive and infiltrative growth pattern and is characterized by an
abundant tumor stroma known to interact with the cancer cells, and to influence tumor growth and drug
resistance. Cancer cells actively take part in the production of extracellular matrix proteins, which then become
deposited into the tumor stroma. Type IV collagen, an important component of the basement membrane, is highly
expressed by pancreatic cancer cells both in vivo and in vitro. In this study, the cellular effects of type IV collagen
produced by the cancer cells were characterized.
Methods: The expression of type IV collagen and its integrin receptors were examined in vivo in human pancreatic
cancer tissue. The cellular effects of type IV collagen were studied in pancreatic cancer cell lines by reducing type IV
collagen expression through RNA interference and by functional receptor blocking of integrins and their binding-sites on
the type IV collagen molecule.
Results: We show that type IV collagen is expressed close to the cancer cells in vivo, forming basement membrane like
structures on the cancer cell surface that colocalize with the integrin receptors. Furthermore, the interaction between
type IV collagen produced by the cancer cell, and integrins on the surface of the cancer cells, are important for
continuous cancer cell growth, maintenance of a migratory phenotype, and for avoiding apoptosis.
Conclusion: We show that type IV collagen provides essential cell survival signals to the pancreatic cancer cells through
an autocrine loop.
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Pancreatic cancer is a disease with extremely poor
prognosis. The five-year survival rate has only improved
marginally over the past decades, and remains at less
than 5% [1,2]. Consequently, pancreatic cancer has the
lowest long-term survival rate among the common ma-
lignancies. The disease typically displays an aggressive,
rapid and infiltrative growth pattern, with metastases
often already seeded at the time of diagnosis.
Pancreatic cancer is characterized by an abundant fi-
brotic tumor stroma, referred to as the desmoplastic re-
action, which surrounds and infiltrates clusters of cancer
cells. Approximately 80% of the tumor mass is made up* Correspondence: malin.sund@surgery.umu.se
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reproduction in any medium, provided the orby the tumor stroma, which is composed of connective
tissue, predominantly type I and type III collagen [3],
but also a variety of other extracellular matrix (ECM)
proteins, blood vessels, inflammatory cells, and activated
pancreatic stellate cells (PSC).
In most situations the PSC is a quiescent fat storing cell,
but after activation morphological changes occur and it be-
comes a highly active matrix-producing myofibroblast-like
cell, expressing large amounts of type I collagen and fi-
bronectin [4]. Pancreatic cancer cells have been shown
to activate the PSC by paracrine mechanisms involving
transforming growth factor-β (TGF-β) [5]. The activated
PSC is the main producer of the stromal ECM, thus,
creating a tumor-supportive microenvironment, resulting
in increased tumor growth [5].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ant for the pronounced drug resistance seen in pancreatic
cancer. Pancreatic cancer cells attached to type I collagen
display increased survival when treated with 5-FU [6], and
interactions with other ECM molecules, such as type IV
collagen, fibronectin, or laminin, also result in decreased
cytotoxicity of anticancer drugs [7]. Furthermore, in a
mouse model of pancreatic cancer, inhibition of the
Hedgehog signaling pathway led to a depletion of the
desmoplastic reaction, and subsequently a better re-
sponse to chemotherapy [8].
Type IV collagen is upregulated in the tumor stroma
and found in discontinuous basement membranes (BM)
[9,10]. We have previously shown that type IV collagen
is highly expressed in close proximity to the pancreatic
cancer cells in vivo [11]. Type IV collagen is the main
component of the BM and provides a scaffold for assem-
bly and mechanical stability, but is also important in cell
adhesion, migration, survival, proliferation, and differen-
tiation [12]. Not only is the activated PSC involved in
the production of the stromal ECM, but the cancer cells
also produce stromal components both in vivo and
in vitro. It has been shown that many pancreatic cancer
cell lines and xenografted human pancreatic tumors ex-
press ECM proteins both at the RNA and protein level,
and most interestingly, type IV collagen synthesis ex-
ceeds that of all other ECM proteins examined, includ-
ing that of type I collagen [13].
Integrin receptors are transmembrane glycoproteins
that are the major cell surface receptors for the ECM,
consisting of one α and one β subunit. Both α1β1 and
α2β1 bind type IV and type I collagens, though α1β1
has a higher affinity for type IV collagen and α2β1 for
type I collagen [12]. Integrin receptors known to bind
type IV collagen (α2β1 and α1β1) are highly expressed
by pancreatic cancer cells [14]. Furthermore, they are
also expressed over the entire cancer cell, not only at
the basolateral side as in normal pancreatic tissue
[15]. Inhibition of integrin β1 has been shown to sup-
press invasion of pancreatic cancer cells in vitro [16].
The integrins have multiple binding-sites on the type
IV collagen molecule, but the major binding-site for
both α1β1 and α2β1 integrins has been identified
within the collagenous domain of type IV collagen
and is referred to as the CB3-region. By using anti-
bodies to block the CB3 region, 80% of cell adhesion
to type IV collagen was inhibited on a variety of car-
cinoma cell lines [17].
In this study we examine the role of cancer cell-
derived type IV collagen and its effects on cancer
growth, apoptosis, and migration, and provide evidence
of type IV collagen as an important autocrine factor for
cancer cell proliferation, survival, and migration in pan-
creatic cancer.Methods
Tissue samples
Tissue samples of pancreatic ductal adenocarcinomas were
collected from patients undergoing a curatively aimed
pancreatico-duodenectomy at the Department of Surgery
at Umeå University Hospital (n = 9). Normal pancreatic tis-
sue samples were collected from patients who underwent
surgery in organs close to the pancreas, but where the dis-
ease did not involve the pancreas (n = 7). Samples were
snap frozen in liquid nitrogen and stored at −80°C until
analysis. This study is approved by the Research Ethics Re-
view Board (EPN) of Northern Sweden.
Cell lines and cell culturing
Two well-characterized human pancreatic adenocarcinoma
cell lines were used. HPAC (ATCC, CRL-2119), a human
pancreatic adenocarcinoma cell line of ductal origin, is de-
rived from a moderate to well differentiated pancreatic
adenocarcinoma [18]. CFPAC-1 (ATCC, CRL- 1918) was
derived from a patient with a ductal adenocarcinoma [19].
HPAC was cultured with 1:1 mixture of Dulbecco’s modi-
fied Eagle’s and Ham’s F12 medium (DMEM/F12),
CFPAC-1 with 90% Iscove’s modified Dulbecco’s medium
(IMDM), both supplemented with 10% fetal calf serum
(FCS), penicillin (105 IU/L), and streptomycin (100 mg/L)
and grown in an incubator at 37°C in an atmosphere with
5% CO2.
Cell and tissue staining
Immunofluorescence stainings were performed on 6 μm
frozen sections, and on cells cultured on Falcon™ Cul-
ture Slides (BD Biosciences, Erembodegem, Belgium)
using methods previously described [20], with the follow-
ing primary antibodies and dilutions: mouse anti-human
integrin α1 (MAB1973, 1:40); mouse anti-human integrin
α2 (MAB1950, 1:40); mouse anti-human integrin β1
(MAB1959, 1:500), all from Millipore (Billerica, MA,
USA); and rabbit anti-human type IV collagen (MP Bio-
medicals, LLC, Solon, OH, USA; cat. no. 10760, 1:100);
goat anti-human type XVIII collagen (R&D Systems,
Minneapolis, MN, USA; AF570, 1:75), goat anti-human
perlecan (R&D Systems, Minneapolis, MN, USA; AF2364,
1:75), rat anti-human laminin-γ1 (Millipore, Billerica, MA,
USA, Mab1914P, 1:75), rabbit anti-human nidogen
(Millipore, Billerica, MA, USA, cat. no. 481978, 1:75),
mouse anti-human cytokeratin 18 (DakoCytomation,
Glostrup, Denmark, DC10 1:100) and sheep anti-CD31
(R&D Systems, Inc., Minneapolis, MN, USA; AF806, 1:50).
Cultured cells were stained with the integrin antibodies
mentioned above together with the goat anti-type IV colla-
gen antibody (Chemicon, Billerica, MA, USA; AB769,
1:50). Double staining on tissue for type I and type IV col-
lagen was performed with a rabbit anti-human type I colla-
gen antibody (Cedarlane Laboratories, Burlington, NC,
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(Wieslab, Malmö, Sweden; MAB1, 1:75) [21]. Secondary
antibodies used were: donkey anti-rabbit FITC, donkey
anti-mouse TRITC and FITC, donkey anti-goat TRITC (all
Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA; with dilutions 1:100). Sections were mounted
with medium containing DAPI (Vectashield, Vector La-
boratories, Inc., Burlingame, CA, USA). Negative control
sections were incubated with secondary antibodies only.
Hematoxylin and eosin (H&E) stainings were performed
according to standard protocols.
Migration, proliferation, and apoptosis assays
Cell proliferation was measured using CellTiter-GloW
(Promega Corporation, Madison, WI, USA), a lumines-
cence based cell viability assay, and cell apoptosis was
assayed with the M30-ApoptosenseW ELISA (Peviva AB,
Bromma, Sweden). In the apoptosis assay the apoptosis-
associated caspase-cleaved cytokeratin 18 is quantita-
tively determined, and high concentrations of the M30
neo-epitope indicate high apoptotic activity. Both assays
were performed according to the manufacturers’ instruc-
tions. For both assays, 5–6 × 103 cells were seeded in
triplicates on 96-well polystyrene plates, culture area
0.34 cm2/well (Nunc, Roskilde, Denmark), with coated
or uncoated surfaces. Proliferation and apoptosis was
measured after 2–3 days incubation, and the cells were
ensured to be in growth phase when assayed (data not
shown). For the apoptosis assay, the triplicates were
pooled together and run in duplicates. Furthermore,
the fraction of cells in S-phase was measured with
flow cytometry, and cells were stained and analyzed
according to standard techniques previously described
[22]. Transfected cells and control cells were solved in
PBS and run in triplicates. DNA histograms were eval-
uated for ploidy (ModFit LT 3.0™, Verity Software
House, Topsham, ME, USA) in order to identify the
fraction of cells in the S-phase.
For the matrix studies, type IV and type I collagen (BD
Biosciences, Two Oak Park, Bedford, MA, USA) and Bo-
vine Serum Albumin (BSA, used as unspecific control
protein) were coated to the wells. For the blocking studies,
wells were coated with antibodies directed against the
NC1, CB3, and 7S domains of the type IV collagen. These
antibodies were: mouse-anti-α1(IV)NC1 (Wieslab, Malmö,
Sweden, MAB1); mouse-anti-α2(IV)7S (Chemicon Inter-
national, Inc., Billerica, MA, USA; MAB1910); mouse anti-
human collagen type IV antibody (Acris Antibodies GmbH,
Herford, Germany; clone CIV22) [23]; and whole mouse
IgG (used as control, Jackson ImmunoResearch Laborator-
ies, Inc.). The coated proteins were diluted in 2 mM hydro-
chloric acid or 10 mM acetic acid, followed by incubation
for 2 hours in the wells. The wells were then washed, cells
added, and grown under FCS free conditions.For the integrin blocking studies, cells were grown in
FCS supplemented medium for one day, washed and
thereafter, the blocking antibody diluted in serum free
medium was added. Antibodies known to functionally
block the integrin receptors and a control IgG antibody
were used (all mentioned above).
Migration was studied in a wound-healing assay, in
which cells were grown on a 24-well wound healing assay
plate (Cell Biolabs, Inc., San Diego, CA, USA), and stan-
dardized wounds (0.9 mm) were generated according to
the manufacturer’s instructions. Two or more wells were
used for each experiment, and pictures were taken every
10 minutes (Olympus IX81 with Cell-R software) with
time-lapse Differential Interference Contrast microscopy
(DIC), and the time of wound closure was determined at
two different locations for each wound. Cells were grown
under FCS supplemented conditions.
RNA interference
CFPAC-1 cells were transfected with a pool of 3 differ-
ent target-specific siRNAs designed to knock down the
gene expression of the COL4A1 gene, and control the
siRNA design to not target any known human gene
(Santa Cruz Biotechnology, Inc., CA, USA, sc-43064 and
sc-37007). Subsequently, 5 x 104 cells/ml were seeded in
6 well plates (Nunc, Roskilde, Denmark), and transfected
according to the manufacturer’s protocol. The down-
regulation of type IV collagen synthesis was verified by
quantitative real time-PCR. Approximately 2x105 cells
from each cell culture were harvested by centrifugation,
and the total RNA was extracted using the RNeasy Mini
Kit (Qiagen GmbH, Hilden, Germany). Equal amounts
(1 μg) of RNA were reverse transcribed into cDNA using
the QuantiTect Reverse Transcription Kit (Qiagen). Gene
expression was quantified using the Bio-Rad iQ SYBR
Green Supermix and the iQ5 iCycler according to the
manufacturer’s instructions. The primer set 50-TGC
ACCACCAACTGCTTAGC-30 and 50-GGCATGGACTG
TGGTCATGAG-30 for the glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) housekeeping gene was used for
normalization, and the primer set 50-CTCTACGTG
CAAGGCAATGA-30 and 50-AGAACAGGAAGGGCAT
TGTG-30, designed using the web-based PCR primer de-
sign tool Primer3 (Rozen and Skaletsky, 2000) was used for
quantification of the COL4A1 gene. All reactions were
run at 95°C for 3 minutes, followed by 40 cycles at 95°C
for 10 seconds and at 60°C for 30 seconds.
Additionally, the type IV collagen protein expression was
detected in the transfected cells using immunofluorescence
staining with the MAB1 antibody. The transfected cells
were assayed for proliferation, apoptosis, and migration as
described above. For the cell proliferation assay, the experi-
ments were repeated five times with similar results both
under FCS free and serum supplemented conditions.
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All assays performed on 96-well plates were run in triplets.
For the M30-ApoptosenseW ELISA, the triplicates were
subsequently pooled and the final analysis was performed
on duplicates of the pooled samples. Normal distribution
was assumed. Unpaired t-test was used when comparing
two groups and ANOVA with Bonferroni post-hoc test if
more than two groups were compared. P < 0.05 was con-
sidered significant. Bars in the figures illustrate the stand-
ard deviation.
Results
Type IV collagen is highly expressed in the stroma of
pancreatic cancer when compared to other basement
membrane proteins
The expression of type IV collagen and other BM proteins
(type XVIII collagen, laminin, nidogen and perlecan) was
studied by immunofluorescence in normal pancreas and
pancreatic cancer tissue. In normal tissue all these BM
proteins have the same expression pattern with expres-

















Figure 1 Expression pattern of integrin receptors and type IV collage
pancreas with acini structures and a duct in the insert. The area shown is r
staining of integrin α1, α2, and β1 (in red), and type IV collagen (green in u
IV collagen is present in the vascular-, ductal-, and acini-BMs. Integrin α1 is
epithelium. Integrin β1 is found in the ductal-, endothelial-, and at the base
Magnification x40 in all panels. Cell nuclei are stained by DAPI (in blue).Figure S1). However, in cancer distinctly different expres-
sion patterns were observed, with high expression of type
IV collagen in vicinity of the cancer cells. Perlecan and
nidogen expression was also observed in the stroma, al-
though the staining pattern and intensity was lower than
that observed for type IV collagen. For type XVIII colla-
gen and laminin only little expression was observed in
the tumor stroma (Additional file 1: Figure S1).
Type IV collagen is highly expressed in close proximity to
the pancreatic cancer cells and colocalizes with integrin
α1, α2, and β1 on the cancer cell surface
The expression pattern of type IV collagen in relation to
the integrin receptors known to bind type IV collagen
(α1β1 and α2β1) was examined with immunofluorescence
both in normal pancreas and in pancreatic cancer tissue.
In normal tissue (Figure 1 and Additional file 2: Figure S2),
type IV collagen is present in the vascular-, ductal-, and
acini-BMs. Integrin α1 is only expressed in the endothelial
cells, whereas α2 is exclusively expressed at the basolateral
surface of the ductal cells. Integrin β1 is expressed in therin α2 Integrin β1
n in normal pancreatic tissue. A. H&E staining of normal exocrine
epresentative for all panels in B. B. Merged immunofluorescence
pper row), or the endothelial marker CD31 (green in lower row). Type
only expressed in endothelial cells and integrin α2 only in the ductal
of the acini-cells. Arrows indicate examples of colocalization.
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ductal and acini cells.
In pancreatic cancer tissue (Figure 2 and Additional
file 3: Figure S3), the expression pattern of type IV colla-
gen and the integrin subunits were examined in both
well- and moderately differentiated pancreatic cancer.
Regardless of the differentiation grade, type IV collagen
is highly expressed in close proximity to the cancer cells,
forming BM like structures surrounding the cancer cells.
Both integrin α2 and β1 are expressed by the cancer
cells, not only basolaterally, but all over the cell surface,
and they colocalize with type IV collagen. Integrin β1 is
also expressed by the endothelial cells, as is integrin α1.
Moreover, in moderately differentiated cancer cells in-
tegrin α1 is sporadically expressed by cancer cells and
partly colocalized with type IV collagen.
Type IV collagen is also highly expressed at the surface
of pancreatic cancer cells in vitro (Figure 3 and Additional
file 4: Figure S4) and colocalizes with integrin α2 and β1.
Integrin α1 is mostly found intracellular and less at the cell
surface.
Both type I and type IV collagens promote growth and
migration and inhibit apoptosis, but are expressed in
different stromal compartments
In pancreatic cancer type I collagen is predominantly
expressed in the desmoplastic reaction that surrounds and
infiltrates clusters of cancer cells (Figure 4A). However,
most of the cancer cells are not in direct contact with type
I collagen. Type IV collagen, on the other hand, is highly
expressed in close relation to all cancer cells.
Pancreatic cancer cells were grown on both type I or
type IV collagen matrices, and both types of collagen
promote cell growth when compared to a control pro-
tein matrix (Figure 4B). Furthermore, there was a ten-
dency of having reduced induction of apoptosis when
the pancreatic cancer cells were grown on collagen
matrices (Figure 4C). Migration was measured in a
wound-healing assay, in which cells were grown on the
different collagens and the time of wound closure was
compared to cells grown on a control matrix (Figure 4D).
The wounds of cells grown on a collagen matrix closed
faster than wounds grown on the control matrix, indi-
cating that cells in contact with type I or type IV colla-
gens develop a more migratory phenotype.
Type IV collagen is an important autocrine factor
regulating growth and migration in pancreas cancer cells
In order to further study the interaction between type
IV collagen and the integrin receptors observed in pan-
creatic cancer tissue, a series of in vitro experiments
were performed in pancreatic cancer cell lines, where
different targets in the type IV collagen-integrin axis
were manipulated (Figure 5).By blocking the integrin receptors α1, α2, and β1 a de-
crease in cell growth was observed (Figure 5A). For integ-
rin α1 and β1 this growth inhibition was dose dependent.
The integrin receptors predominantly bind to the CB3
region of the type IV collagen molecule, but also to the
NC1 domain [12]. By blocking these binding sites with
region-specific antibodies, a decrease in cell growth was
seen when blocking the CB3 region, but not when
blocking the NC1 domain (Figure 5B). The 7S domain is
not known to bind to any integrins; hence, blocking this
domain did not affect cancer cell growth.
Down-regulation of α1(IV) synthesis was achieved
through RNA interference and verified on both the
mRNA and protein level (Figure 5C-1). With qRT-PCR,
the down-regulation was approximated to a 0.45-fold re-
duction in α1(V)-transcripts compared with cells
transfected with control siRNA. This reduction of en-
dogenous type IV collagen expression in pancreatic can-
cer cells led to a 20% decrease in cell growth 40 hours
after transfection, when compared to cells transfected
with control (nonsense) siRNA (Figure 5C-2). The re-
duction in cell growth was also confirmed by measuring
the S-phase (Figure 5C-2 insert). Control cells showed a
S-phase of 28.6% compared to 22.6% for the α1(IV)-
siRNA transfected cells. In the wound-healing assay, the
α1(IV)-siRNA transfected cells showed a less migratory
phenotype compared to the control transfected cells
(Figure 5C-3 and Additional file 5: Movie S1). In
addition, an increased induction of apoptosis was ob-
served in the α1(IV)-siRNA transfected cells when com-
pared with control siRNA transfected cells (Figure 5C-4),
indicating that cancer cell-produced type IV collagens can
have a protective role against apoptosis.
Furthermore, the reduction of cell growth induced by
down-regulation of α1(IV) synthesis was normalized
when the cells were grown on a type IV collagen matrix
(Figure 5D). This growth rescue effect was not achieved
if the cells were grown on a control matrix composed of
BSA. Moreover, the rescue once again failed if integrin
β1 receptors were blocked during the time the α1(IV)-
siRNA transfected cells were grown at the type IV colla-
gen matrix (Figure 5D).
Together, these data demonstrate the importance of
type IV collagen/integrin receptor interactions and
shows that type IV collagen is an important autocrine
factor, regulating growth, migration, and apoptosis in
pancreas cancer cells.
Discussion
Previous studies have shown that many integrin recep-
tors are expressed in pancreatic cancer cells [14,16].
Type IV collagen is produced by the cancer cells, and is
deposited in direct proximity to the cancer cells in the
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Figure 2 Expression pattern of integrin receptors and type IV collagen in pancreatic cancer tissue. A. H&E staining of representative areas of a
well (in B) and moderately (in C) differentiated pancreatic adenocarcinoma. Clusters of tumor cells (T) surrounded by desmoplastic stroma (D). B. Merged
immunofluorescence double staining of integrin α1, α2, and β1 (in red), and type IV collagen (green in upper row), or the endothelial marker CD31 (green
in lower row). Type IV collagen is highly expressed in close vicinity to the cancer cells, forming BM like structures around small clusters of cancer cells.
Integrin α2 and β1 are expressed on cancer cells, and these receptors colocalize with type IV collagen (in yellow). Integrin α1 and β1 are expressed in the
endothelial basement membrane, as indicated by colocalization with CD31. C. In moderately differentiated cancer the same expression pattern as in well
differentiated cancer can be seen, but integrin α1 is sporadically expressed in cancer cells. Close-up in inserts (magnification x100), all other panels with a
magnification of x40. Arrows indicate examples of colocalization. Cell nuclei are stained by DAPI (in blue).
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unknown. This is not the case for all BM proteins as
shown in this study, which indicates that these proteins
although expressed in the same structure in normal pan-
creas tissue, can have different functions in pancreatic
cancer. Cancer is a clonal disease and the cancer cells
seen in an advanced cancer are all results of many cell
generations of active selection, where the cells most fit-
ted for rapid expansion have gained a growth advantage.
Protein synthesis is an energy consuming process for all
cells, and if type IV collagen synthesis was not of import-
ance for cancer progression, clones with lower collagen
production would have emerged and gained advantage
in the cancer cell population. Thus, the observed accu-
mulation of BM like structures close to the cancer cells
both in vivo and in vitro must mean that type IV colla-
gen is, somehow, important for the cancer cells. In this
study we show that type IV collagen colocalizes with
integrins known to bind type IV collagen on the cancer
cell surface both in vivo and in vitro, and that the inter-
action between the CB3 region of the type IV collagen
molecule, and integrin receptors (especially β1) on the
surface of the cancer cells, is an important factor that
stimulates proliferation and migration, and inhibits
apoptosis in pancreatic cancer cells. This finding also
gives a rationale for the abundant deposition of type IV
collagen seen in human pancreatic cancer tissue.
Furthermore, we show that type I collagen also pro-
motes cancer cell proliferation, migration, and regulates
apoptosis, in the same extent as type IV collagen, but
that these two collagen types are expressed in different
compartments of the tumor stroma in vivo. The PSC are
located in the desmoplastic area and are the main pro-
ducers of type I collagen in the stroma, but most cancer
cells are not in direct contact with type I collagen,
whereas type IV collagen is produced by the cancer cells
themselves, and forms BM like structures surrounding
clusters of cancer cells. Taken together, although it is
likely that both type I and type IV collagens areFigure 3 Expression of integrin receptors in pancreatic cancer cell lin
in green. Type IV collagen is highly expressed by pancreatic cancer cells. In
at the cell surface. Integrin α2 and β1 are expressed and partly colocalized with
the figure HPAC cells are shown, but similar expression pattern was seen withimportant for pancreatic cancer progression, they might
have distinct roles in the pathogenesis of pancreatic
cancer.
The integrin-ECM axis in pancreatic cancer is believed
to play an important role in regulating growth and mi-
gration of pancreatic cancer cells [7]. Mutations in pan-
creatic cancer cells lead to constitutive activation of
TGF-β1, which in turn results in the proliferation of
pancreatic stellate cells (PSC) [7]. PSCs produce the type
I collagen and fibronectin found in the desmoplasia,
which in turn mediates cancer cell proliferation and mi-
gration through integrin receptors (α2β1 for type I colla-
gen and α5β1 for fibronectin)[7]. In addition to this
paracrine mechanism, based on our findings, we provide
evidence of an autocrine loop of endogenous type IV
collagen produced by the pancreatic cancer cell, import-
ant in regulating growth, apoptosis, and migration in
pancreatic cancer. We hypothesize that pancreatic can-
cer cells, by producing BM proteins such as type IV col-
lagen, form their own BM-like structures that the cancer
cells, in an autocrine manner, can anchor to and conse-
quently, achieve sustained cell growth, avoid apoptosis,
and develop a migratory phenotype.
Our data show that reduced production of endogenous
type IV collagen, blocking of the CB3-region on the type
IV collagen molecule and blocking of the integrin β1 re-
ceptor, all lead to a pronounced growth inhibition. How-
ever, the antibody we used to block the CB3-region has
been shown not to affect the binding of integrin α1β1 to
type IV collagen [23]. As expression of integrin α1
in vivo was only occasionally observed on pancreatic
cancer cells, and was found mostly intracellular in vitro,
our results indicate that integrin α1 is of less importance
for the interaction we have studied, and that integrin β1
in combination with another α subunit, forming dimers
with affinity to the CB3-region, causes the observed
effects.
Attachment to the BM is crucial for the survival and
growth of the epithelial cells. Integrin receptors play anes. Merged images with type IV collagen in red and integrin receptors
tegrin α1 is expressed, but is found also intracellularly, not exclusively
type IV collagen (in yellow). Cell nuclei are stained by DAPI (in blue). In
CPFAC-1.
Figure 4 Expression patterns of type I and type IV collagen and their effect on cell growth. A. Double staining of type I (in green) and
type IV collagen (in red) in a pancreatic adenocarcinoma. Cell nuclei are stained by DAPI (in blue). Type I collagen is predominantly found in the
desmoplastic reaction (D) that surrounds and partly infiltrates clusters of tumor cells (T). Type IV collagen is highly expressed in close proximity to
the tumor cells with lower expression in the desmoplastic area. Magnification x40. B. Growth of pancreatic cancer cells on different matrices after
2 days of incubation. Both type I and type IV collagens promote growth when compared to BSA (used as control protein) in all different coating
concentrations (p < 0.05). C. Apoptosis measured with the M30-ApoptosenseW ELISA after 48 h incubation in serum free conditions with cells
grown on different matrices. Type IV collagen inhibits induction of apoptosis compared to a control BSA matrix (* indicates p < 0.05 compared to
BSA). D. Time for wound-healing closure for cells grown on different matrices (coated with 0.5 μg/cm2). * indicates p < 0.05 compared to BSA.
Picture-inserts represent the size of the wound at 445 minutes, when the wound on the type I collagen matrix was closed (dotted line indicates
cell front). Figures B, C, and D are all based on data from HPAC, but similar results were observed for CFPAC-1.


























































































































































































































Figure 5 (See legend on next page.)
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Figure 5 Cellular effects of type IV collagen. A. Blocking of integrin α1, α2, and β1 resulted in reduced growth compared to control IgG (‡ indicates
p<0.05 compared to index 1.0). Blocking of α1 and β1 showed dose dependency (*indicates p<0.05 compared to 1 μg/ml). B. Effects on cell growth after
incubation with antibodies blocking different domains of type IV collagen, presented as relative growth compared to cells incubated with unspecific
control IgG antibody (index 1.0). Blocking of the CB3-region reduces growth dose dependently (‡ indicates p<0.05 compared to index 1.0 and *indicates
p<0.05 compared to 0.1 μg/cm2). C-1. Down-regulation of type IV collagen expression at the protein level (α1(IV) in red and DAPI in blue) and the mRNA
level in α1(IV) siRNA transfected cells. C-2. Reduced cell growth after down-regulation of the α1(IV)-chain. ‡ indicates p<0.05. Growth inhibition was
measurable after 20 hours and the effect sustained for 70 hours. Inserts illustrate differences in S-phase, p=0.03. C-3. Wound-healing assay for α1(IV)- and
control-siRNA transfected cells. Picture-inserts represent the size of the wound at 83s, when the wound in the control cells was closed. *indicates p<0.05
compared to control transfected cells. C-4. Increased levels of the apoptotic M30-neoepitope were observed in α1(IV)-siRNA transfected cells (p=0.03).
D. Under serum free conditions, α1(IV)-siRNA transfected cells show reduced growth. The cell growth is rescued if α1(IV)-siRNA transfected cells are
grown on an exogenous type IV collagen matrix. Blocking of integrin β1 inhibits the rescue effect, whereas addition of a control IgG antibody does
not. If α1(IV)-siRNA transfected cells are grown on an unspecific matrix (BSA), a small positive but non-significant effect on growth was observed.
*indicates p<0.05 compared to α1(IV)-siRNA transfected cells grown without any coated matrix and without any blocking antibodies, and ‡ indicates
p < 0.05 compared to control-siRNA transfected cells.
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http://www.biomedcentral.com/1471-2407/13/154important role in anchoring the cells and in providing sur-
vival signals, and if the epithelial cell loses contact with the
BM, apoptosis is initiated [24,25]. Pancreatic adenocarcin-
oma is of epithelial origin, and in the transformation
process this mechanism must be overrun; otherwise, apop-
tosis will be induced as soon as the BM is degraded in order
to make subsequent tumor growth possible. We believe
that pancreatic cancer cells, by producing their own BM,
gain proliferative and invasive properties of crucial import-
ance for the pathogenesis of pancreatic cancer. We have
studied type IV collagen, one of the most abundant compo-
nents of all BM and highly expressed by pancreatic cancer
cells [9,10,13]. Most certainly other BM proteins are pro-
duced and show similar autocrine effects, and we show
here that proteins such as nidogen and perlecan are also
found in the tumor stroma. Therefore, the tumor produced
BM might conceal future therapeutic targets that will be
important for the development of new treatment strategies
for pancreatic cancer.
Conclusion
In this study we demonstrate that type IV collagen is
produced by the pancreatic cancer cells and forms BM
like structures surrounding the cancer cells. Through an
autocrine loop, type IV collagen interacts with integrin
receptors on the surface on the cancer cells, and stimu-
lates pancreatic cancer cell proliferation, migration, and
inhibits apoptosis.
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Additional files
Additional file 1: Figure S1. The expression pattern of various basement
membrane (BM) proteins and cytokeratin 18 (CK18) in normal pancreas and
pancreatic cancer tissue. No CK 18 expression was observed in normal tissueas expected, whereas strong expression by pancreatic cancer cells can be
seen (B,D, F, H and J). The expression patterns of all the BM proteins are the
same in normal pancreas tissue (A, C, E, G and I). However, in pancreatic
cancer tissue an intensive staining can be observed in the tumor stroma of
type IV collagen (B). For nidogen (H) and perlecan (J) staining in tumor
stroma can be seen, whereas only weak staining can be observed for type
XVIII collagen (D) and the gamma-1 chain of laminin (F).
Additional file 2: Figure S2. The expression pattern of integrin
receptors and type IV collagen in normal pancreas tissue shown as single
channels. The same pictures as in Figure 1B but the different channels
are presented individually and not merged.
Additional file 3: Figure S3. Expression pattern of integrin receptors
and type IV collagen in pancreatic cancer tissue shown as single
channels. The same pictures as in the inserts (x100 magnification) of
Figure 2B and Figure 2C, but the different channels are presented
individually and not merged. A represents well differentiated and B
moderately differentiated pancreatic adenocarcinoma.
Additional file 4: Figure S4. Expression of integrin receptors in
pancreatic cancer cell lines shown as single channels. The same pictures
as Figure 3 but the different channels are presented individually and not
merged.
Additional file 5: Movie S1. Difference in migration for α1- and control-
transfected cells. Movie that illustrates the difference in migratory capacity
between α1(IV)-siRNA transfected and control-siRNA transfected cells.
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